Crowdfunding an investment in AI, Longevity & Pain Management
Limited Chance for Investors Looking to Own a Stake in: The Future of AI Preventative Healthcare
Chronic disease is a $4.5[1] trillion problem killing millions every year. The U.S. healthcare system waits for people to get sick before doing anything.
Only 1% [2] of healthcare spending goes to prevention. Patients are done waiting—they’re spending their own money on early detection and real solutions.
🔥 That’s why AI in medical imaging is exploding—from $1B to $15.3B by 2032[3].
🔥 Infrared imaging in healthcare? Doubling from $6.75B to $12.78B by 2031[4].
🚀 Oxygen4Life isn’t following the trend—we’re leading it.
💡 Are you ready? Keep reading.
Chronic disease is a $4.5[1] trillion problem killing millions every year. The U.S. healthcare system waits for people to get sick before doing anything.
Only 1% [2] of healthcare spending goes to prevention. Patients are done waiting—they’re spending their own money on early detection and real solutions.
🔥 That’s why AI in medical imaging is exploding—from $1B to $15.3B by 2032[3].
🔥 Infrared imaging in healthcare? Doubling from $6.75B to $12.78B by 2031[4].
🚀 Oxygen4Life isn’t following the trend—we’re leading it.
💡 Are you ready? Keep reading.
Amount Raised to Date: $9,944.85
Stock Type: Common Stock
Share Price
$11.91
Min. Investment
$297.75*
Raise Amount
$123,995.78
Pre-Money Valuation
$125M
*3.5% investor processing fee will be added to all investments
Limited Chance for Investors Looking to Own a Stake in:
The Future of AI Preventative Healthcare
Chronic disease is a $4 trillion problem killing millions every year. The U.S. healthcare system waits for people to get sick before doing anything.
Only 2.5% of healthcare spending goes to prevention. Patients are done waiting—they’re spending their own money on early detection and real solutions.
🔥 That’s why AI in medical imaging is exploding—from $1B to $14.4B by 2032.
🔥 Infrared imaging in healthcare? Doubling from $6.75B to $12.77B by 2031.
🚀 Oxygen4Life isn’t following the trend—we’re leading it.
💡 Early investors in this space are positioned to capture exponential growth. Are you ready? Keep reading.
Chronic disease is a $4 trillion problem killing millions every year. The U.S. healthcare system waits for people to get sick before doing anything.
Only 2.5% of healthcare spending goes to prevention. Patients are done waiting—they’re spending their own money on early detection and real solutions.
🔥 That’s why AI in medical imaging is exploding—from $1B to $14.4B by 2032.
🔥 Infrared imaging in healthcare? Doubling from $6.75B to $12.77B by 2031.
🚀 Oxygen4Life isn’t following the trend—we’re leading it.
💡 Early investors in this space are positioned to capture exponential growth. Are you ready? Keep reading.
Stock Type: Common Stock
Share Price: $11.91
Min. Investment: $297.75*
Raise Amount: $123,900
*3.5% investor processing fee will be added to all investments
Pre-Money Valuation: $125,000,000
⚠️ The Problem: Healthcare is Reactive, Not Proactive
70% of deaths in the U.S. are linked to chronic inflammatory diseases like heart disease, neuropathy, and diabetes.[5]
The current diagnostic system only detects problems once symptoms are severe, leaving millions untreated.
The U.S. spends $4 trillion annually on chronic disease care—but most solutions treat symptoms, not the root cause.
The current diagnostic system only detects problems once symptoms are severe, leaving millions untreated.
The U.S. spends $4 trillion annually on chronic disease care—but most solutions treat symptoms, not the root cause.
There has to be a better way... Oxygen4Life, Inc. IS that way...
🚀 The Future of Healing is Here, and It’s Already Changing Lives
What if millions of deaths from chronic inflammation, neuropathy, and cardiovascular disease could be prevented?
What if medicine wasn’t just about treating symptoms—but actually detecting problems early enough to reverse damage before it’s too late?
What if healing wasn’t just reactive—but proactive, AI-driven, and personalized?
🔥 That future isn’t decades away. It’s happening NOW.
For the millions suffering from chronic inflammation, a silent killer that underlies conditions like diabetes, heart disease, and neurodegeneration…
For veterans and first responders struggling with PTSD and TBI, forced to navigate a healthcare system that reacts too late…
For diabetic patients at risk of neuropathy and foot ulcers, facing life-altering amputations…
For the millions unknowingly walking around with vascular disease, with no way of detecting it until a major event like a heart attack or stroke strikes...
🚀 There is a better way. And it’s already here!
A Shift is Happening and It’s Moving Faster Than Ever.
🔹 AI is revolutionizing diagnostics. The market for AI in medical imaging is skyrocketing—from $1B to $14.4B by 2032.[3]
🔹 Infrared imaging in healthcare is becoming a world wide standard. Expected to nearly double from $6.75B to $12.78B by 2031.[4]
🔹 Preventative medicine is no longer optional. Consumers are tired of reactive healthcare and are investing in solutions that detect disease before it happens.
💡 The healthcare industry is transforming. The investors who recognize this shift early are the ones who win.
And at the center of this transformation? Oxygen4Life.
🔥 Not just another biotech company. Not a supplement. Not another drug. Not just a diagnostic tool.
🚀 FDA-cleared, AI-powered system for early detection AND management of chronic inflammation and disease.
The Investment Opportunity:
A Rare Chance to Get in Early on the Future of Healthcare
A Rare Chance to Get in Early on the Future of Healthcare
Imagine a world where chronic diseases like neuropathy, cardiovascular disease, and others are detected before they spiral out of control.
Where patients no longer have to wait until they’re sick to get answers.
Where AI, infrared imaging, and science-backed inflammation management combine to redefine preventative healthcare—saving millions of lives and billions in healthcare costs.
Now, imagine being able to invest in that future before the rest of the world catches on.
🚀 Oxygen4Life is not a concept. It’s happening now.
✅ FDA-cleared technology is already in use
✅ Proprietary AI-driven database with over 1,000,000 medical images
✅ A patented medical food designed for inflammation management
✅ A physician training platform accelerating adoption across clinics, hospitals, and practitioners worldwide
Moments like these are rare for investors. Just think about it:
Think about the early investors in most industries, they were positioned for the biggest growth.
What was the difference between those who made life-changing returns and those who didn’t? TIMING!
Minimum Investment - $297.75*
The Market Size of Chronic Inflammatory Diseases
🔹 Chronic inflammatory diseases like heart disease, diabetes, and neurodegenerative disorders account for 70% of deaths in the U.S., contributing to a $4 trillion healthcare burden.
🔹 Diabetes-related complications cost the U.S. healthcare system $327 billion annually, with Diabetic Peripheral Neuropathy (DPN) alone ranging from $4.6B to $13.7B per year.[6]
🔹 PTSD & Traumatic Brain Injury (TBI) impact millions of veterans and first responders, with over $100 billion spent annually on treatment and disability costs.[7]
🔹 Vascular diseases such as stroke, peripheral artery disease, and cardiovascular disorders contribute to 1 in 3 deaths globally, with an estimated economic impact of $363 billion annually.[8]
🔹 Chronic wounds and diabetic foot ulcers (DFUs) represent a $28B–$31.7B healthcare challenge, leading to over 80,000 amputations per year in the U.S. alone.[9]
🔹 Neurodegenerative diseases like Alzheimer’s cost the U.S. over $345 billion per year, with projections reaching $1 trillion by 2050.[11]
🔹 Autoimmune diseases, including conditions like rheumatoid arthritis and lupus, impact over 24 million Americans, with total healthcare spending exceeding $100 billion annually.[12]
Inflammation is the silent killer behind all of these diseases.
Diseases that cripple lives, and are draining trillions from the healthcare system.
Inflammation is the silent killer behind all of these diseases. Disease that crippling lives, and draining trillions from the healthcare system.
💡 The Solution: AI-Driven Diagnostics + Proven Treatments
Oxygen4Life, Inc. combines FDA-cleared medical imaging, AI diagnostics, and patented therapeutic solutions to detect, track, and manage chronic diseases before they escalate.
💡 Fix the inflammation problem and you change everything.
🔹 Cut billions in wasted healthcare costs
🔹 Improve patient outcomes—helping people live longer, healthier, and more functional lives
🔹 Empower medical practitioners to keep more revenue in-house while delivering better care
🔥 The system is broken. The cost is staggering. The opportunity to fix it is here.
This Is Not a "What If" Scenario, It’s Happening NOW.
This isn’t a theory. It isn’t a future concept. It’s already in motion.
🔬 Our Game-Changing Product-Line:
1. ThermaLens™ IRIS-XP - Infrared Imaging System
FDA Cleared - Medical Infrared Imaging System
✅ ThermaLens™ IRIS-XP is non-invasive, FDA-cleared and ready for immediate use by physicians, clinics, and government healthcare providers. Unlike competitors still in clinical trials, our technology is already in the hands of practitioners. It combines a high-resolution, infrared camera, with a proprietary artificial intelligence software for fast, accurate, and automatic disease detection.
This system can precisely measures a patient's heat signature to within a fraction of a degree, then use machine learning to cross-reference this data with our extensive database of verified medical cases.[13]
This enables for the early detection of conditions such as:
Diabetic foot ulcers, breast cancer, circulatory diseases, neuropathy, chronic inflammation, peripheral artery disease, and more.
This enables for the early detection of conditions such as:
Diabetic foot ulcers, breast cancer, circulatory diseases, neuropathy, chronic inflammation, peripheral artery disease, and more.
2. AiLLUMI™ - AI Powered Diagnostics
AiLLUMI™: The AI-Powered Diagnostic Breakthrough that transforms lives.
🔹 A proprietary database of over 1,000,000 infrared medical images—making it one of the largest AI-driven thermal imaging datasets in the world.
🔹 Provides instant, data-backed diagnostic insights to help medical professionals detect inflammation, vascular disease, neuropathy, PTSD, and more—before symptoms escalate.
🔹 Continuously learning and evolving—every new scan refines the system’s accuracy, ensuring practitioners get the most precise, real-time analysis possible.
🔹 Bridges the gap between AI and clinical decision-making, allowing faster, more accurate diagnoses and better patient outcomes.
With AiLLUMI™, practitioners don’t just see the problem—they understand it, predict it, and act before it’s too late.
Watch the diagnostic video below
Comprehensive care doesn't stop with early detection
Addressing the underlying conditions is equally as important.
3. Brivanta™ - Patented Organic Medical Food
Brivanta™ is a plant-based, cold-pressed, and organic Essential Fatty Acid formulation, specifically designed as a medical food for those with an impaired Delta-6 Desaturase Enzymatic Pathway.
As we age, the Delta-6 Desaturase enzymatic pathway is known to become impaired.⁷ This impairment has been linked to multiple chronic inflammatory diseases and immune-deficiencies.
With over two decades in development, Brivanta™ offers a targeted dietary management approach for chronic inflammation. Today, the modern diet unknowingly may cause chronic inflammation leading to ill-health.[14][15] Inflammatory response starts with the Delta-6 Desaturase enzymatic pathway.[16]
Targeted Relief: Provides relief to those battling chronic inflammatory diseases due to a Delta-6 Desaturase Pathway impairment.
Physician Supervised: This medical food is exclusively available under the guidance of a licensed physician.
Patented & Proven: Patents granted in the United States and Canada, backed by over 20 years of evidence-based research and development.
Easy Administration: Brivanta™, is an oil that remains liquid even at cold temperatures, and should be stored in the fridge to prevent rancidity. It comes with a small measuring spoon for easy and precise dosing.
Brivanta™ falls under the orphan drug act and is only available through a licensed MD.
How Does Brivanta™ Work?
What Diseases, Disorders, and Impairments Does Brivanta™ manage?
Brivanta™ helps facilitate the production of eicosanoids, important signaling molecules for the body, as shown below
What Is A Medical Food?
"The term medical food, as defined in section 5(b) of the Orphan Drug Act (21 U.S.C. 360ee (b) (3)) is "a food which is formulated to be consumed or administered enterally under the supervision of a physician and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation."
Manufacturers of medical foods must comply with all applicable FDA requirements for foods, including the following regulations:
Manufacturers of medical foods must comply with all applicable FDA requirements for foods, including the following regulations:
• Current good manufacturing practice (21 CFR part 110);
• Registration of food facilities (21 CFR part 1 subpart H);
• Thermally processed low-acid foods packaged in hermetically sealed containers (21 CFR part 113);
• Acidified foods (21 CFR part 114); and
• Emergency permit control (21 CFR part 108).
Medical foods are not drugs and, therefore, are not subject to any regulatory requirements that specifically apply to drugs. Medical foods are also not health supplements which can not make medical claims.
Examples of Brivanta™
CASE 1: Progression of Brivanta™ in Chronic DFU Patient*
- 60-year-old Hispanic male with history of PVD and Diabetes presents with right planter sub 5th metatarsal open wound
- This had been the 4th time it has opened in the past 8 years with two previous ulcers healing in 50 weeks and 54 weeks.
- Using Brivanta™, the ulcer healed in 46 weeks, with a healing improvement of 15%
CASE 2: Progression of Brivanta™ in Venous Ulcer Patient*
CASE 3: Progression of Brivanta™ in Pressure Ulcer Patient*
- 57-year-old white male presents with ischemic eschar of the 2nd right digit and eschar of the anterior distal hallux with pain on palpation.
- Told by the vascular service that it would likely demarcate and he would lose the digit. Patient was treated with betadine and Brivanta™ 5cc, 5-days-a-week. Healing time was 9 weeks.
*past results do not guarantee future results
4. InfraREDMed™ - first-of-its-kind physician training platform
InfraREDMed™: A first-of-its-kind physician training platform, ensuring high adoption and effective integration into healthcare systems.
🔹 The world’s leading physician training platform for infrared medical imaging.
🔹 Built on decades of research and clinical expertise, providing medical professionals with certification, hands-on training, and advanced diagnostic education.
🔹 Seamlessly integrates with ThermaLens™ and AiLLUMI™, ensuring practitioners can effectively use AI-driven infrared imaging for early detection of inflammation, vascular disease, and neuropathy.
🔹 A critical bridge between cutting-edge technology and real-world application, empowering doctors, clinics, and hospitals to adopt AI-powered diagnostics and proactive inflammation management.
🔥 InfraREDMed™ isn’t just a training platform—it’s the backbone of the infrared medical community, ensuring rapid adoption and expert-level execution worldwide.
We don’t just diagnose problems. We help fix them.
🌍 Market Opportunity – A Multi-Billion Dollar Industry
The future of healthcare is non-invasive, AI-driven, and preventive.
Oxygen4Life is leading the way.
The Team Behind Oxygen4Life™, Inc.
Mike Maunu -CEO/President & Founder
*Click here to learn more about Mike*
Alex Maunu - Co-Founder, Director of Marketing
*Click here to learn more about Alex*
Dr. Marcos Brioschi MD -Chief Medical Officer
*Click here to learn more about Marcos*
Dionisio Gomez -Director of online marketing
*Click here to learn more about Dionisio*
Keith McAslan -CFO/Board of Advisors
*Click here to learn more about Keith*
Tom Winckler - Director of Strategic Partnerships/Investor Relations
Cindi Webb - Director of Training & Onboarding for medical practitioner's
*Click here to learn more about Cindi*
Board of Advisors:
Dr. Guy Peterson MD
(Medical Advisor)
Dr. Guy Peterson is a board certified anesthesiologist with 38 years in the medical field, currently practicing in men's health. Medical advisor at Holistic Freedom Institute for neuro conscious healing. Designing therapies for improving symptoms of Traumatic Brain Injury.
Dr. Guy Peterson is a board certified anesthesiologist with 38 years in the medical field, currently practicing in men's health. Medical advisor at Holistic Freedom Institute for neuro conscious healing. Designing therapies for improving symptoms of Traumatic Brain Injury.
Prof. David Blackledge, Atty
(Government Contracting and Growth Advisor)
David Blackledge is fulltime faculty Professor at Grand Canyon University’s College of Business and Of Counsel at Davis Miles McGuire Gardner, a full service law firm operating in the southwest US.
David Blackledge is fulltime faculty Professor at Grand Canyon University’s College of Business and Of Counsel at Davis Miles McGuire Gardner, a full service law firm operating in the southwest US.
Investment Opportunity: Be Part of the Next Healthcare Giant!
📈 Comparable Company Valuations - Why $125M is Conservative
A Unique Window of Opportunity
Oxygen4Life, Inc has the infrastructure, the regulatory clearance, and the technology to transform the $4 trillion chronic disease market.
And just like the biggest healthcare giants before their rise, this is the pre-public moment where the potential upside is at its highest.
Imagine walking into a VA clinic, a hospital, or a doctor’s office and seeing Oxygen4Life’s technology at work—knowing you had the chance to invest before this company became a household name.
Imagine the potential of major healthcare players acquiring Oxygen4Life to integrate its AI diagnostics and medical imaging innovations into their ecosystem.
Big names in healthcare have made billion-dollar acquisitions for far less.
This could be one of the last chances to invest in Oxygen4Life before it scales.
The company is raising $123,995.78 in this round—and as the industry shifts toward AI-powered, non-invasive healthcare, the potential for growth is massive.
When you get in on the right company early, the long-term impact can be life-changing.
The only question is: Will you be watching from the sidelines—or will you be part of the next major shift in healthcare?
(Forward looking Projections cannot be guaranteed. See broader Forward Looking Statement Disclosure at the endnote)
Click Here to View the disclosure
Click Here to View the disclosure
USE OF FUNDS:
Audited Financials and Funding Amendment: Completing audited financials through 2024 to meet regulatory requirements and amending the funding target of this campaign to $5,000,000, less amounts already raised, to align with the company's long-term growth strategy.
Medical Conferences & Events: Costs associated with attending major medical and tech conferences, including booth setup, marketing materials, travel, and accommodation.
Dealmaker Fees: Expenses to our broker/dealer for the current crowdfunding raise.
Personnel : Oxygen4Life, Inc. is currently a lean operation. Covers the cost of compensating our Chief Medical Officer (CMO) and providing stipends for other key team members contributing to critical operational activities.
Marketing & Advertising: : Digital advertising, SEO, content marketing, and PR campaigns focused on customer acquisition and improving online visibility in the medical and health tech sectors.
Investment Packages and Bonuses:
All investments above $2,500 Receive Additional Bonus Shares!
Investor Based:
Existing Investors: - 5% bonus shares
Time Based:
First 30 days – 5% bonus shares
Second 30 days – 2% bonus shares
Amount Based:
USD $2500.00 investment – 5% bonus shares
USD $5000.00 investment - 7% bonus shares
USD $10,000.00 investment - 9% bonus shares
USD $25,000.00 investment - 12% bonus shares
USD $50,000.00 investment - 15% bonus shares
1)All perks occur after the offering is completed.
2) For the time-based perks, the 1st 30 days begins upon the filing of the Form C being reflected on the SEC's EDGAR System and concludes on the 30th day at 11:59 PM Pacific Standard Time (6:59 AM UTC the next day: (UTC plus 7)).
3) The 2nd 30 days begins at the conclusion of the 1st 30 days and concludes on the 60th day at 11:59 PM Pacific Standard Time (6:59 AM UTC the next day: (UTC plus 7)).
4) In order to receive perks from an investment, one must submit in a single subscription for the total investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks will be assessed and issued after the offering is completed.
5) All bonus shares are the same as the shares being sold under this offering.
6) Bonus shares can be stacked with one per category. Eg; existing investor, time based and amount based can all be combined.
Existing Investors: - 5% bonus shares
Time Based:
First 30 days – 5% bonus shares
Second 30 days – 2% bonus shares
Amount Based:
USD $2500.00 investment – 5% bonus shares
USD $5000.00 investment - 7% bonus shares
USD $10,000.00 investment - 9% bonus shares
USD $25,000.00 investment - 12% bonus shares
USD $50,000.00 investment - 15% bonus shares
1)All perks occur after the offering is completed.
2) For the time-based perks, the 1st 30 days begins upon the filing of the Form C being reflected on the SEC's EDGAR System and concludes on the 30th day at 11:59 PM Pacific Standard Time (6:59 AM UTC the next day: (UTC plus 7)).
3) The 2nd 30 days begins at the conclusion of the 1st 30 days and concludes on the 60th day at 11:59 PM Pacific Standard Time (6:59 AM UTC the next day: (UTC plus 7)).
4) In order to receive perks from an investment, one must submit in a single subscription for the total investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks will be assessed and issued after the offering is completed.
5) All bonus shares are the same as the shares being sold under this offering.
6) Bonus shares can be stacked with one per category. Eg; existing investor, time based and amount based can all be combined.
CUSTOM JAVASCRIPT / HTML
Copyrights 2025 | All Rights Reserved
| Oxygen4life.com | Oxygen4Lifeinc.com | Oxygen4Life™, Inc. |
These statements have not been evaluated by the Food and Drug Administration. These products and statements are not intended to diagnose, treat, cure or prevent any disease or illness. These statements should not be taken as medical advice, you should always consult your doctor before making any health changes, decisions and/or drawing any health conclusions.
This site is not a part of the Facebook website or Facebook Inc. Additionally, This site is NOT endorsed by Facebook in any way. FACEBOOK is a trademark of FACEBOOK, Inc.
This site is not a part of the Facebook website or Facebook Inc. Additionally, This site is NOT endorsed by Facebook in any way. FACEBOOK is a trademark of FACEBOOK, Inc.
Citations and References:
¹ https://www.cdc.gov/chronic-disease/data-research/facts-stats/index.html
² https://www.proventionhealth.org/chronic-disease-prevention-an-important-key-to-improving-life-and-healthcare-systems-today/#:~:text=Today%2C%20only%20a%20fraction%20of,Disease%20Prevention%20and%20Health%20Promotion.
³ https://linkewire.com/2025/02/21/ai-in-medical-imaging-market/
⁴ https://www.fortunebusinessinsights.com/infrared-imaging-market-102601
⁵ https://archive.cdc.gov/www_cdc_gov/nccdphp/dch/about/index.htm
⁶ https://www.coherentmi.com/industry-reports/diabetic-peripheral-neuropathy-market
⁷https://www.hsrd.research.va.gov/research/citations/pubbriefs/articles.cfm?RecordID=1177
⁸ https://www.vox.com/future-perfect/373495/chronic-disease-global-rates-cancer-diabetes-noncommunicable
⁹ https://www.liebertpub.com/doi/10.1089/wound.2019.0946
¹¹ https://www.cbsnews.com/news/alzheimers-costs-americans-277-billion-a-year-report/
¹² https://www.hcplive.com/view/autoimmune-diseases-cost-us-more-than-100-billion-annually
¹³ Aliahmad B, Tint A, Arjunan SP, Rani P, Kumar D, Miller J, Zajac J, Wang G, Ekinci E. "Is Thermal Imaging a Useful Predictor of the Status". Journal of Diabetes Science and Technology. 2018 Sep 26. Available from: https://www.semanticscholar.org/paper/Is-Thermal-Imaging-a-Useful-Predictor-of-the-Status-Aliahmad-Tint/fd2dd26a4cfa3e17dd0fc14e6ba6ccbf3a9da9b1
¹⁴ Torres M, Parets S, Fernández-Díaz J, Beteta-Göbel R, et al. "Lipids in Pathophysiology and Development of the Membrane Lipid Therapy: New Bioactive Lipids". Department of Biology, University of the Balearic Islands. Membranes (Basel). 2021 Dec; 11(12): 919. Available from: https://pubmed.ncbi.nlm.nih.gov/34940418/
¹⁵ Horrobin DF. "Loss of D-6 desaturase activity as a key factor in aging". Medical Hypothesis. 1981 Sep;7(9):1211-20. Available from: https://www.sciencedirect.com/science/article/abs/pii/0306987781900645
¹⁶ Lee JM, Lee H, Kang SB, Park WJ, et al. "Fatty Acid Desaturases, Polyunsaturated Fatty Acid Regulation, and Biotechnological Advances". Department of Horticultural Science, Kyungpook National University. Nutrients. 2016 Jan 4; 8(1): 23. Available from: https://www.mdpi.com/2072-6643/8/1/23
17 https://www.sec.gov/Archives/edgar/data/1823182/000110465922102825/0001104659-22-102825-index.htm
18 https://www.picmiicrowdfunding.com/deal/IdentifySensors%20Biologics/?
18 https://www.picmiicrowdfunding.com/deal/IdentifySensors%20Biologics/?
19 https://www.maginative.com/article/spotify-founders-health-tech-startup-neko-raises-260m-valued-at-1-8-billion
20 https://pitchbook.com/profiles/company/278149-33
21 https://invest.birchbiomed.com/?
22 https://wefunder.com/senjam/
Oxygen4Life, Inc. is offering securities through the use of an Offering Statement that has been qualified by the Securities and Exchange Commission under Title III of the JOBS Act and Regulation CF. A copy of the Form C that forms a part of the Offering Statement may be obtained from: Form C
Equity crowdfunding investments in private placements, and start-up investments in particular, are speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investment through equity crowdfunding tend to be in earlier stages of development and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Any past performance described is not indicative of future results. Further, investors may receive illiquid and/or restricted stock that may be subject to holding period requirements and/or liquidity concerns.
DealMaker Securities LLC, a registered broker-dealer, and member of FINRA | SIPC, located at 4000 Eagle Point Corporate Drive, Suite 950, Birmingham, AL 35242, is the Intermediary for this offering and is not an affiliate of or connected with the Issuer. Please check our background on FINRA's BrokerCheck.
Equity crowdfunding investments in private placements, and start-up investments in particular, are speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investment through equity crowdfunding tend to be in earlier stages of development and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Any past performance described is not indicative of future results. Further, investors may receive illiquid and/or restricted stock that may be subject to holding period requirements and/or liquidity concerns.
DealMaker Securities LLC, a registered broker-dealer, and member of FINRA | SIPC, located at 4000 Eagle Point Corporate Drive, Suite 950, Birmingham, AL 35242, is the Intermediary for this offering and is not an affiliate of or connected with the Issuer. Please check our background on FINRA's BrokerCheck.
DealMaker Securities LLC does not make investment recommendations.
DealMaker Securities LLC is NOT placing or selling these securities on behalf of the Issuer.
DealMaker Securities LLC is NOT soliciting this investment or making any recommendations by collecting, reviewing, and processing an Investor’s documentation for this investment.
DealMaker Securities LLC conducts Anti-Money Laundering, Identity and Bad Actor Disqualification reviews of the Issuer, and confirms they are a registered business in good standing.
DealMaker Securities LLC is NOT vetting or approving the information provided by the Issuer or the Issuer itself.
Contact information is provided for Investors to make inquiries and requests to DealMaker Securities LLC regarding Regulation CF in general, or the status of such investor’s submitted documentation, specifically. DealMaker Securities LLC may direct Investors to specific sections of the Offering Circular to locate information or answers to their inquiry but does not opine or provide guidance on issuer related matters.
This website contains forward-looking statements. These statements may include the words “believe”, “expect”, “anticipate”, “intend”, “plan”, “estimate”, “project”, “will”, “may”, “targeting” and similar expressions as well as statements other than statements of historical facts including, without limitation, those regarding the financial position, business strategy, plans, targets and objectives of the management of Oxygen4Life, Inc. for future operations (including development plans and objectives). Such forward-looking statements involve known and unknown risks, uncertainties and other important factors which may affect the Company's ability to implement and achieve the economic and monetary policies, budgetary plans, fiscal guidelines and other development benchmarks set out in such forward-looking statements and which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future policies and plans and the environment in which the Company will operate in the future. Furthermore, certain forward-looking statements are based on assumptions or future events which may not prove to be accurate, and no reliance whatsoever should be placed on any forward-looking statements in this presentation. The forward-looking statements in this website speak only as of the date of the Company's initial Form C, and the Company expressly disclaims to the fullest extent permitted by law any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.